Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2010 - 2026)

Catalyst Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$9.2 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 260.78% year-over-year to -$9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.5 million (down 59.11% YoY) and the FY2025 annual result came in at $24.2 million, down 55.13% from the prior year.
• Change in Accured Expenses was -$9.2 million for Q1 2026 at Catalyst Pharmaceuticals, down from $5.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $20.0 million in Q3 2024 and bottomed at -$9.2 million in Q1 2026.
• A 5-year average of $5.4 million and a median of $8.2 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 316.77% — and 2024, when it jumped 449.88%.
• Catalyst Pharmaceuticals' Change in Accured Expenses stood at $11.5 million in 2022, then retreated by 28.82% to $8.2 million in 2023, then advanced by 8.67% to $8.9 million in 2024, then plunged by 41.46% to $5.2 million in 2025, then plunged by 276.72% to -$9.2 million in 2026.
• Business Quant data shows CPRX's Change in Accured Expenses at -$9.2 million in Q1 2026, $5.2 million in Q4 2025, and $13.2 million in Q3 2025.